EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 180 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Large Study Confirms that HPV Vaccine Prevents Cervical Cancer October 14, 2020 Inspired By Her Mom’s Breast Cancer Battle, Girl Sells ‘Cancer Bears’... March 11, 2021 FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer August 16, 2022 Worried Cancer Patients Face Delayed Treatment Because Of Pandemic April 1, 2020 Load more HOT NEWS Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer New analysis estimates over 21 million UK adults will be obese... Câncer em minha comunidade: Trabalhando para expandir o acesso a estudos... Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers
